ORIC to Participate at Citi 13th Annual Biotech Investor Conference
SAN FRANCISCO, Aug. 30, 2018 — ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, announced today that it will be participating in Citi’s 13th Annual Biotech Conference in Boston on September 5th. On Wednesday, September 5, 2018 at 11:15 am ET, Jacob Chacko, MD, Chief Executive Officer, will participate in a panel discussion entitled, “Emerging Innovators – An Introduction to Biotech Privates.”
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC’s lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC’s pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC’s scientific founders are Drs. Charles Sawyers, MD and Scott Lowe, PhD, who have records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.
<< Back to News